Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer

• Published in: Oncogene Vol. 37; no. 42; pp. 5682 - 5693
• Main Authors: Golfmann, Kristina, Meder, Lydia, Koker, Mirjam, Volz, Caroline, Borchmann, Sven, Tharun, Lars, Dietlein, Felix, Malchers, Florian, Florin, Alexandra, Büttner, Reinhard, Rosen, Neal, Rodrik-Outmezguine, Vanessa, Hallek, Michael, Ullrich, Roland T.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.10.2018; Nature Publishing Group
• Subjects: 13; 13/95; 59/5; 631/67/1059; 631/67/1347; 64/60; AKT protein; Angiogenesis; Angiogenesis Inhibitors - pharmacology; Animals; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Apoptosis; Autocrine signalling; Breast cancer; Breast Neoplasms - pathology; Cancer patients; Cancer treatment; Care and treatment; Cell Biology; Cell Line, Tumor; Cell proliferation; Clinical trials; Development and progression; Drug Synergism; Endothelial growth factors; Endothelium; Female; Fibroblast growth factor receptor 1; Fibroblast growth factor receptors; Fibroblast growth factors; Gene amplification; Genetic aspects; Growth factor receptors; Health aspects; Heterografts; Human Genetics; Humans; Innovations; Internal Medicine; MAP kinase; Medicine; Medicine & Public Health; Mice; Mice, Inbred NOD; Molecular targeted therapy; Naphthalenes - pharmacology; Neovascularization, Pathologic; Oncology; Patients; Phenylurea Compounds - pharmacology; Phosphorylation; Piperidines - pharmacology; Pyrimidines - pharmacology; Quinazolines - pharmacology; Quinolines - pharmacology; Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors; Secretion; Tumors; Vascular endothelial growth factor; Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors; Vascular endothelial growth factor receptors
• ISSN: 0950-9232; 1476-5594
• DOI: 10.1038/s41388-018-0380-3

FGFR1 amplification has been found in 15% of patients with breast cancer and has been postulated as a promising marker to predict response against FGFR inhibitors. However, early phase clinical trials of selective FGFR inhibitors demonstrated only limited efficacy in FGFR1 -amplified breast cancer patients. We found that BGJ398, an FGFR inhibitor, effectively inhibited phosphorylation of FGFR1 and MEK/ERK signaling in FGFR1- amplified breast cancer without affecting tumor cell proliferation. However, FGFR1 knockout inhibited tumor angiogenesis in vivo. We unraveled that FGFR1 regulates the secretion of the proangiogenic vascular endothelial growth factor (VEGF) in a MAPK-dependent manner. We further found that FGF-FGFR1 signaling induces an autocrine activation of VEGF-VEGFR1 pathway that again amplifies VEGF secretion via VEGF-VEGFR1-AKT signaling. Targeting both VEGFR1 and FGFR1 resulted in synergistic anti-angiogenic treatment effects in vivo. We thus postulate synergistic treatment effects in FGFR1/VEGFR1-positive breast cancer patients by dual targeting of FGFR and VEGFR.